53. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 45 or 51 or the pharmaceutical composition of claim 52 for use as a medicament.

54. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 45 or 51 or the pharmaceutical composition of claim 52 for use in the treatment of a disease in an individual in need thereof.

55. The T cell activating bispecific antigen binding molecule or the pharmaceutical composition of claim 54, wherein the disease is cancer.

56. Use of the T cell activating bispecific antigen binding molecule of any one of claims 1 to 45 or 51 for the manufacture of a medicament for the treatment of a disease in an individual in need thereof.

57. A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the T cell activating bispecific antigen binding molecule of any one of claims 1 to 45 or 51 in a pharmaceutically acceptable form.

58. The use of claim 56 or the method of claim 57, wherein said disease is cancer.

59. A method for inducing lysis of a target cell, comprising contacting a target cell with the T cell activating bispecific antigen binding molecule of any one of claims 1-45 or 51 in the presence of a T cell.

~~60. The invention as described hereinbefore.~~